Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Losina, E., E. E. Dervan, A. D. Paltiel, Y. Dong, R. J. Wright, K. P. Spindler, L. A. Mandl, et al. 2015. "Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis." PLoS ONE 10 (6): e0130256. doi:10.1371/journal.pone.0130256. http://dx.doi.org/10.1371/journal.pone.0130256.

Published Version
doi:10.1371/journal.pone.0130256

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295531

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
RESEARCH ARTICLE

Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis

Elena Losina1,2,3,4*, Elizabeth E. Dervan1,2,3,4a, A. David Paltiel5, Yan Dong5b, R. John Wright6, Kurt P. Spindler7, Lisa A. Mandl6,9, Morgan H. Jones7, Robert G. Marx8,9, Clare E. Safran-Norton10, Jeffrey N. Katz1,2,3,11

1 Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 2 Section of Clinical Sciences, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 3 Harvard Medical School, Boston, Massachusetts, United States of America, 4 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America, 5 Yale School of Public Health and Yale School of Management, New Haven, Connecticut, United States of America, 6 Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 7 Department of Orthopaedic Surgery, Cleveland Clinic, Garfield Heights, Ohio, United States of America, 8 Weill Cornell Medical College, New York, New York, United States of America, 9 Hospital for Special Surgery, New York, New York, United States of America, 10 Department of Rehabilitation Services, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 11 Departments of Epidemiology and Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America

a Current address: Yale Law School, New Haven, Connecticut, United States of America
b Current address: OPKO Health, Inc., Woburn, Massachusetts, United States of America
* elosina@partners.org

Abstract

Background

Arthroscopic partial meniscectomy (APM) is extensively used to relieve pain in patients with symptomatic meniscal tear (MT) and knee osteoarthritis (OA). Recent studies have failed to show the superiority of APM compared to other treatments. We aim to examine whether existing evidence is sufficient to reject use of APM as a cost-effective treatment for MT+OA.

Methods

We built a patient-level microsimulation using Monte Carlo methods and evaluated three strategies: Physical therapy (‘PT’) alone; PT followed by APM if subjects continued to experience pain (‘Delayed APM’); and ‘Immediate APM’. Our subject population was US adults with symptomatic MT and knee OA over a 10 year time horizon. We assessed treatment outcomes using societal costs, quality-adjusted life years (QALYs), and calculated incremental cost-effectiveness ratios (ICERs), incorporating productivity costs as a sensitivity analysis. We also conducted a value-of-information analysis using probabilistic sensitivity analyses.
and Joint Surgery, EED: none, ADP: Past Secretary Treasurer, Society for Medical Decision Making, YD: none, RJW: DePuy, a Johnson & Johnson Company, KPS: Arthritis Foundation; American Orthopaedic Society for Sports Medicine; NFL Charities Safety Panel, LAM: Assistant Editor, Annals of Internal Medicine, MHU: Allergan, Inc, RGM: Senior Associate Editor, HSS Journal; Associate Editor, Journal of Bone and Joint Surgery; Springer: Demos Health; Member-at-Large, International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine, CESN: none, JNK: Deputy Editor, Journal of Bone and Joint Surgery; President-Elect, Osteoarthritis Research Society International. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Results

Calculated ICERs were estimated to be $12,900/QALY for Delayed APM as compared to PT and $103,200/QALY for Immediate APM as compared to Delayed APM. In sensitivity analyses, inclusion of time costs made Delayed APM cost-saving as compared to PT. Improving efficacy of Delayed APM led to higher incremental costs and lower incremental effectiveness of Immediate APM in comparison to Delayed APM. Probabilistic sensitivity analyses indicated that PT had 3.0% probability of being cost-effective at a willingness-to-pay (WTP) threshold of $50,000/QALY. Delayed APM was cost effective 57.7% of the time at WTP = $50,000/QALY and 50.2% at WTP = $100,000/QALY. The probability of Immediate APM being cost-effective did not exceed 50% unless WTP exceeded $103,000/QALY.

Conclusions

We conclude that current cost-effectiveness evidence does not support unqualified rejection of either Immediate or Delayed APM for the treatment of MT+OA. The amount to which society would be willing to pay for additional information on treatment outcomes greatly exceeds the cost of conducting another randomized controlled trial on APM.

Introduction

Meniscal tear (MT) is a highly prevalent condition, particularly for individuals over age 50 and those with concomitant knee osteoarthritis (OA) [1]. Symptomatic MT is often treated surgically with arthroscopic partial meniscectomy (APM), a widespread procedure performed in over 350,000 people annually between the ages of 45 and 64 in the US [2].

Five recent randomized controlled trials (RCTs) have evaluated APM efficacy among symptomatic patients with MT and radiographic or pre-radiographic knee OA. One most recent study established the superiority of APM compared to non-operative management [3], while others failed to establish superiority of APM compared to non-operative management or sham procedures, demonstrating similar pain relief between surgical and non-surgical interventions [4–8]. In three of these studies, between 20% and 30% of patients originally assigned to the non-surgical arm crossed over to receive APM [3–6]. A recent meta-analysis concluded that over a short time horizon (6 months), APM is superior to non-operative management, but this superiority is not observed over a longer time horizon [9]. These data raise questions about the value of APM in patients with MT and knee OA. The high cross-over rates suggest that the most clinically effective treatment may be physical therapy (PT) followed by Delayed APM for those with persistent symptoms.

While these papers offer insight into the efficacy of APM vs. PT in persons with MT and OA, the economic implications of these treatments have not yet been evaluated. On the basis of these trials, some payers may consider revising reimbursement policies for APM. As various reimbursement policies are considered, a formal decision analysis may offer critical insight regarding the value of alternative treatment strategies.

We used decision analysis modeling informed by data from the Meniscal Tear in Osteoarthritis Research (MeTeOR) trial [6] to evaluate the long-term clinical and economic implications of alternative treatment strategies for symptomatic patients presenting with MT and osteoarthritic changes. Additionally, we used formal decision analysis and cost-effectiveness...
methods to determine the level of confidence regarding optimal decision choices and the value of further related research in this area.

**Methods**

**Analytic Overview**

We used a cost-effectiveness framework to evaluate three different treatment strategies: 1) physical therapy alone (‘PT’), 2) PT followed by APM only for subjects still symptomatic three months after physical therapy (‘Delayed APM’), and 3) APM offered as first line treatment to all subjects (‘Immediate APM’). Each strategy allowed subjects to proceed to total knee arthroplasty (TKA) if they demonstrated radiographic evidence of advanced knee OA as well as sustained pain.

We built a probabilistic Markov state-transition, computer-based simulation model in which a subject’s experience was described by a sequence of transitions among distinct health states. We evaluated the three strategies over ten years using quarterly cycles, meaning transitions between health states could occur in the model every three months of a subject’s life. Health states were defined by a subject’s knee pain status, treatment, and extent of radiographic progression. Health states were associated with distinct economic costs and decrements to health-related quality of life (QoL), outcomes which subjects accrued as they transitioned from one health state to another [10].

Subjects entered the model with knee OA at Kellgren-Lawrence (KL) grades 0, 1, 2 or 3 [11]. A subject’s knee OA could progress structurally throughout the model, causing a subject to transition to a health state with potentially higher costs and lower QoL. Data for clinical and economic parameters were derived from the MeTeOR study for the first year after treatment and from national OA cohort studies for subsequent years.

To determine the value of different strategies for MT treatment, we conducted a cost-effectiveness analysis in accordance with recommendations of the US Panel of Cost-Effectiveness in Health and Medicine [12]. Preferences for health states were defined by ‘utilities’ that reflect societal preferences for different health states on a scale of 1.00 (perfect health) to 0.00 (death) [13]. Main outcomes for the analyses included quality-adjusted life years (QALYs) and costs accumulated over the 10-year lifespan. QALYs and costs were reported on a present-value basis using an annual discount rate of 3%. Cost-effectiveness for each treatment strategy was expressed in terms of incremental cost-effectiveness ratios (ICERs), or additional costs incurred for every QALY gained.

We employed probabilistic Monte Carlo simulation methods, which take into consideration uncertainty in the several key parameters. We used beta distributions to model the probabilities of failed pain relief, pain incidence and pain resolution post-treatment, and gamma distributions to model costs [14]. Further details on choice of parameter distributions are presented in the S1 Technical Appendix. Using the results of 10,000 simulations, we constructed a cost-effectiveness acceptability curve by repeating the Monte Carlo simulation multiple times, building a scatter plot of different realizations, and then determining the proportion of those simulations where a given strategy was ‘preferred’ under a range of willingness to pay (WTP) thresholds. A strategy was called ‘preferred’ if it had the highest probability of having the highest net monetary benefit (NMB) of all strategies under consideration. NMB is defined as a difference between a product of WTP and strategy effectiveness minus the costs associated with that treatment strategy [15].

Uncertainty in parameters leads to the possibility of making the wrong treatment decision, which may lead to increased costs and/or worse health benefits. However, the reduction or elimination of uncertainty through additional research comes at a cost. We used novel
methodology to quantify the value of future research to reduce uncertainty in efficacy and costs parameters by estimating expected value of perfect information (EVPI). EVPI measures the difference between the total costs associated with the best possible decision that could be made with additional information compared to the potential costs of the best decision that could be made in the absence of any additional information [15].

Since uncertainty surrounded a sizable number of parameters in our analysis, we also estimated the expected value of partial perfect information (EVPPI), which limits this value-based assessment of future research to a subset of a model’s parameters. Importantly, by valuing uncertainty within each group of parameters, EVPPI can help inform the comparative prioritization of future studies. We then estimated the population value-of-information (VOI) by multiplying per person EVPI by the number of persons expected to encounter treatment decisions during the usable time of information. This approach is particularly important when evaluating common procedures such as APM.

Model Structure
Subjects moved across the following major health states in the model (Fig 1): 1) initial treatment (APM or PT); 2) early moderate or low pain; and 3) late moderate or low pain. Pain-related health states were stratified by KL grade. Subjects could elect TKA if they had advanced knee OA (KL grades 3 or 4) as well as pain for at least 6 consecutive months after the initial 3-month treatment period. TKA uptake rate was determined according to utilization rates derived from the Multicenter Osteoarthritis Study and Osteoarthritis Initiative cohorts [16]. Death was possible at any state.

Cohort Characteristics
We generated a cohort reflective of the MeTeOR study population. Subjects entered the simulation model with an average age of 58 and the following distribution of OA severity: 44.8% KL grades 0 or 1, 26.4% KL grade 2, and 28.8% KL grade 3 [6]. Annual mortality was derived from the 2009 intercensal US Life Tables published by the Centers for Disease Control and Prevention [17]. Incidence and structural progression of knee OA were derived from the Johnston County Osteoarthritis Project [18].

Input Parameters
A substantial number of input parameters were required for the microsimulation. They are presented in Table 1 as well as in the S1 Technical Appendix.

Pain Relief and Incidence. Distributions of pain relief three months after initial treatment (APM or PT) were derived from the MeTeOR study using a transformed Knee injury and Osteoarthritis Outcome Score (KOOS) Pain scale (Table 1). The KOOS scale is a validated measure of knee pain that ranges from 0 to 100, where 100 represents the highest possible level of pain [34,35]. Pain in the model was dichotomized at a KOOS score of 25, with scores above 25 characterized as ‘Moderate Pain’ and scores at or below 25 as ‘Low Pain.’ This threshold was chosen to reflect that scores below 25 correspond to mild pain on a majority of domains on the KOOS scale [35].

Based on the expert opinion of a panel of MeTeOR clinical investigators (RJW, KPS, LAM, MHJ, JNK), we assumed that changes in pain status attributable to a specific treatment should be limited to the first six months following that treatment. Subjects who experienced pain relief at 3 months were able to experience late pain by month 6; similarly, subjects who reported initial failure in pain relief were able to experience pain resolution in the next quarter. Transition probabilities for pain and pain resolution were stratified by OA severity (Table 1). Distributions
of the parameters used in our Monte Carlo analysis appear as histograms in S1 Technical Appendix Table A-5.
### Table 1. Base Case Parameters.

| Cohort Characteristics | Source |
|------------------------|--------|
| Age, Mean (SD)*        | 58 (7) | Katz et al. 2013 [6] |
| **OA Prevalence at Baseline** | | Katz et al. 2013 [6]; Johnston County Osteoarthritis Project [18]; Holt et al. 2011 [19] |
| KL grade 0 and 1       | 44.8%  | |
| KL grade 2             | 26.4%  | |
| KL grade 3             | 28.8%  | |
| KL grade 4             | 0.0%   | |
| **Annual KL Progression** | | |
| KL 2 to KL 3           | 0.0735 | |
| KL 3 to KL 4           | 0.0267 | |
| **Annual OA Incidence, by Age** | | Losina et al. 2013 [20]; Weinstein et al. 2013 [16] |
| 45–54                  | 0.379% | |
| 55–64                  | 0.668% | |
| 65–74                  | 0.375% | |
| 75–84                  | 0.306% | |
| 85+                    | 0.310% | |
| **Quality of Life Utility Scores** | | Katz et al. 2013 [6] |
| Low Pain (KOOS < 25)   | 0.869  | |
| High Pain (KOOS > 25)  | 0.771  | |
| **Pain after MT Treatment*‡** | | Katz et al. 2013 [6] |
| Months 0 to 3 post Treatment | APM | APM after PT | PT |
| Probability of Failed Pain Relief | | | | |
| KL grade 0, 1, 2       | 0.322, Beta (29, 61) | 0.400, Beta (6, 9) | 0.569, Beta (58, 44) |
| KL grade 3, 4          | 0.488, Beta (21, 22) | 0.667, Beta (6, 3) | 0.703, Beta (26, 11) |
| Probability of Pain Incidence | | | |
| KL grade 0, 1, 2       | 0.230, Beta (14, 47) | 0 | 0.227, Beta (10, 34) |
| KL grade 3, 4          | 0.364, Beta (8, 14) | 0 | 0.182, Beta (2, 9) |
| Probability of Pain Resolution | | | |
| KL grade 0, 1, 2       | 0.483, Beta (14, 15) | 0 | 0.155, Beta (9, 49) |
| KL grade 3, 4          | 0.333, Beta (7, 14) | 0 | 0.115, Beta (3, 23) |

### Knee-OA Related Pain

| Annual Pain by KL | Pain Incidence | Pain Resolution | Source |
|-------------------|----------------|----------------|--------|
| KL grade 0, 1     | 0.075          | 0.085          | Johnston County Osteoarthritis Project [18] |
| KL grade 2        | 0.085          | 0.037          | |
| KL grade 3        | 0.212          | 0.040          | |
| KL grade 4        | 0.190          | 0.005          | |
Table 1. (Continued)

| Cohort Characteristics | Source |
|------------------------|--------|
| TKA, Annual Efficacy   |        |
| Pain Relief            | Katz et al. 2007 [21] |
| First year             | 0.862  |
| Subsequent years       | 0.960  |

| Perioperative Outcomes and Adverse Events (AE) |
|-----------------------------------------------|
| Treatment                       | Probability of AE | Mortality, given AE |
| APM                             | 0.015             | 0.011               |
| TKA                             | 0.036             | 0.006               |
| Pharmacologic pain management   | 0.111             | 0.005               |

| Costs, Quarterly‡ |
|-------------------|
| Mean              |
| PSA Distribution  |
| Alpha, Lambda     |
| Healthcare Costs and Treatment of Pain |
| Cost of APM       |
| Procedure         | $2,867            |
| Complication      | $11,589           |
| Healthcare, post-op pain* | $454 Gamma 703, 1.5 |
| PT Rehabilitation* | $439 Gamma 351, 0.8 |
| Cost of PT Regimen* |
| Healthcare, post-op pain | $209 Gamma 117, 0.6 |
| PT Rehabilitation | $568 Gamma 352, 0.6 |
| Cost of Pain Management*‡‡ |
| High Pain cohort   | $276 Gamma 129, 0.5 |
| Low Pain cohort    | $99 Gamma 160, 1.6 |
| Complication       | $1,816            |
| Cost of TKA†       |
| Procedure and rehab| $20,282           |
| Complication       | $15,149           |

| Indirect Costs: Productivity Losses, in hours lost* |
|-----------------------------------------------------|
| Katz et al. 2013 [6]; Bureau of Labor Statistics 2013 [33] |
| Months 0 to 3                                       |
| APM                                                 | 109 Gamma 79, 0.7 |
| PT                                                  | 79 Gamma 22, 0.3 |
| Months 3 to 6                                       |
| High Pain                                           | 87 Gamma 32, 0.4 |
| Low Pain                                            | 42 Gamma 68, 1.6 |
| After 6 months                                      |
| High Pain                                           | 70 Gamma 94, 1.4 |
| Low Pain                                            | 30 Gamma 89, 3.0 |

* All distributions were sampled in a probabilistic sensitivity analysis (PSA); parameters for these distributions are included in this table.
† Includes total cost of care and rehabilitation following treatment regimen.
‡ All probabilities for changes in pain reported as quarterly probabilities unless otherwise specified
‡‡ Includes cost of select NSAIDs, opioids, acetaminophen, intra-articular injections, visits to the ER, medical appointments, and alternative medicines/therapies.

doi:10.1371/journal.pone.0130256.t001
Six months after initiation of the index treatment, incidence and resolution of knee pain were assumed to be due to changes in subjects’ underlying knee OA. Values associated with the probability of fluctuations in OA-related knee pain were derived from the Johnston County Osteoarthritis Project [18] and were stratified according to KL grade (Table 1).

**Efficacy of Delayed APM.** Due to limited data on the efficacy of APM if pain was not relieved by initial PT, we considered two scenarios for estimating the efficacy of a Delayed APM procedure. In our base case analysis, we used a more conservative scenario and derived a distribution of being in moderate pain after Delayed APM from subjects in the MeTeOR study that were randomized to PT but crossed over to APM three months post-randomization. The 3-month time point for this analysis was chosen in consultation with a number of practicing clinical investigators (both surgeons and physical therapists), who stated that after a three month trial of PT, patients are generally re-evaluated and surgery is considered if PT has not been beneficial. In a sensitivity analysis, we assumed that the efficacy of APM in those who failed PT would be the same as in subjects who had undergone APM initially, as their primary treatment.

**Quality of Life Estimates.** Utilities were derived from the MeTeOR study, where study participants were asked to fill out the EQ-5D instrument [6], a validated measure of QoL across five dimensions of health [36,37]. Health states defined by the EQ-5D descriptive system were matched to a reference set of weights that corresponded to each state’s utility value [38]. These weights were averaged among those with moderate and low pain to create final utility values (Table 1).

**Adverse Events.** Adverse events could occur following APM, TKA, and ingestion of pain medications. Values for the incidence, cost, and mortality associated with these adverse events are shown in Table 1 and the S1 Technical Appendix.

**Medical Costs.** Costs fell into one of two categories: 1) direct medical costs for the treatment of knee pain due to either MT or OA and 2) costs of productivity lost due to treatment and functional disability. These costs appear in Table 1 and are reported in 2013 US Dollars (USD). Utilization of PT sessions for subjects in the PT and the Delayed APM arms were derived from the PT-randomized arm in the MeTeOR trial, while utilization of PT in the Immediate APM arm was derived from the APM-randomized arm in the MeTeOR trial. These costs are the total costs of PT and only applied to the cycles where PT was used. Subjects also accumulated costs over time due to general medical care, which included scheduled office visits to healthcare providers, trips to the emergency room, and management of knee pain with NSAIDs, opioids, acetaminophen, intra-articular injections, or alternative therapies. Unit costs were derived from Medicare Fee Schedules, Red Book Online, and published literature [27,28,30,39]; a detailed derivation is presented in the S1 Technical Appendix. Utilization of health services and pain control were derived from the MeTeOR trial and stratified by pain severity.

**Time Costs.** Time costs were defined by the number of hours individuals were unable to work as a result of knee pain or time spent undergoing medical care, including surgery, recovery, and PT (Table 1). Time costs also accounted for suboptimal productivity at work. The number of wage-earning hours lost per person in each treatment strategy was taken from the MeTeOR Trial and multiplied by the national mean hourly wage, $22.33/hour [33]. Productivity losses during the first 6 months were derived directly from the data from the MeTeOR trial, and these derivations took into account both employed and unemployed groups. For those who were not employed, we assigned no productivity losses. Overall productivity losses were computed as a weighted average of losses among employed and unemployed. Productivity losses for the longer time frame took into consideration the data from the Bureau of Labor Statistics on the likelihood of employment by age and sex, adjusting subjects’ estimated time costs.
according to their diminished likelihood of employment over the course of the 10 year time-frame [40]. The derivation of these time costs appears in the 
S1 Technical Appendix (Tables A-4a and A-4b).

Analyses

Base Case. In the base case analysis, we assumed that APM did not influence OA progression. We did not include time costs. We used conservative estimates of Delayed APM efficacy derived from MeTeOR subjects who crossed over from PT to the APM arm between 3 and 6 months.

Sensitivity Analysis. We conducted sensitivity analyses that considered alternative scenarios regarding the efficacy of Delayed APM and inclusion of time costs. We conducted a two-way sensitivity analysis in which we simultaneously varied two model parameters identified as critical for the treatment decision-making process by MeTeOR investigators: 1) the potential impact of APM on OA progression and 2) the potential impact of delaying the surgical procedure on its overall efficacy (S1 Technical Appendix). We also conducted a sensitivity analysis reducing the time horizon of analysis from 10-years to 5-years.

Ethics Approval

This study was approved by the Partners Human Research Committee, the institutional review board of the parent organization of Brigham and Women’s Hospital. All patients in the MeTeOR trial gave written informed consent for their clinical data to be used in this study [41].

Results

Base Case Analysis

Fig 2 illustrates the proportion of persons in each treatment strategy in moderate pain over the course of 10 years. At 6 months, 60% of subjects in the PT-only treatment strategy experienced moderate pain compared to 38% for both the Delayed and Immediate APM strategies. By five years post-treatment the estimated proportion of persons in moderate pain decreased to 56% for the PT strategy and increased to 47% for both the Delayed and Immediate APM strategies. Cumulative incidence of TKA at 10 years in this population ranged from 15% for the PT-only strategy to 14% for both strategies incorporating APM.

The results of all Monte Carlo simulations are presented in a scatter plot in the S1 Technical Appendix (Fig B-2). Table 2 presents a summary of these averaged results and describes the incremental cost-effectiveness of each strategy. Over 10 years, non-operative treatment led to an estimated 6.637 discounted QALYs compared to 6.723 QALYs for the Delayed APM strategy and 6.732 for the Immediate APM strategy. Subjects who underwent Immediate APM incurred the highest direct medical costs at $12,900; PT and Delayed APM were associated with lower direct medical costs of $10,800 and $11,900, respectively. These resulted in estimated ICERs of $12,900/QALY for Delayed APM compared to PT and $103,200/QALY for Immediate APM compared to Delayed APM.

Sensitivity Analyses

Inclusion of Time Costs. Time costs represented a substantial component of total costs and amounted to $27,400 for the non-operative (PT) strategy, $25,700 for the Delayed APM strategy, and $25,400 for the Immediate APM strategy. With the inclusion of time costs, Delayed APM became cost-saving (i.e. more effective and less expensive) compared to PT.
alone. Including time costs made Immediate APM more cost-effective than in the base case analysis, with an ICER of $72,200/QALY compared to Delayed APM.

Efficacy of Delayed APM. When the efficacy of Delayed APM was made equivalent to that of immediate surgery, Delayed APM produced lower direct medical costs ($11,600) and higher QALYs (6.744) than in the base case analysis, generating an ICER of $7,400/QALY compared to PT (Table 2). Immediate APM became dominated by the Delayed APM strategy, i.e., more expensive with fewer improvements in QALYs. With time costs, Delayed APM became cost-saving compared to PT while Immediate APM remained dominated.

Uncertainty around Cost-Effectiveness and Determination of Preferred Treatment Strategies. Fig 3 displays a cost-effectiveness acceptability curve that describes the proportion of iterations for which each strategy was cost-effective at a given WTP threshold. Fig 4 presents a cost-effectiveness acceptability frontier. For the base case scenario with WTP values below $13,000/QALY, PT alone was the preferred strategy because it yielded the greatest NMB the
highest number of times. Beyond that WTP threshold, PT was no longer preferred because Delayed APM now had the highest number of iterations with the highest NMB.

At a WTP threshold of $100,000/QALY, Delayed APM was the preferred treatment strategy with 50.2% certainty (i.e. choosing what the model described as ‘preferred’ would ultimately prove not to be cost-effective 49.8% of the time). At a WTP of $103,000/QALY, Immediate APM was preferred. Its probability of being preferred did not exceed 53%, even at a WTP of $150,000/QALY.

Fig 4 also displays EVPI as the quantification of the consequences of making a less-than-optimal (in terms of losses in QALYs and increased costs) treatment choice. EVPI was estimated at $734 per person (pp) at WTP $50,000/QALY ($1,649pp at WTP $100,000/QALY). This implies that by eliminating all uncertainty, we can expect an improvement in net monetary benefit of $734pp ($1,649pp) or that the current expected harm due to uncertainty is $734pp ($1,649pp) with a health equivalent of 5.4 quality-adjusted days (6.0 days). Given that about 352,000 persons between the ages of 45 and 64 years undergo APM every year [2], eliminating all uncertainty could lead to an additional 5,164 QALYs (5,804 QALYs) in this population. Assuming a period of 3 years is the usable life of information resulting from efforts to reduce uncertainty and a discount rate of 3%, we estimate that the maximum benefit from additional research designed to eliminate uncertainty related to benefits and costs of treatment of MT in the presence of OA to be $752.3 million at $50,000/QALY WTP ($1.691 billion at $100,000/QALY WTP).

S1 Technical Appendix Fig B-4 describes the impact of individual parameters on model uncertainty and presents a summary of EVPPI estimates for four key parameters. Of these, the efficacy of a delayed APM generated the highest EVPPI value of $376pp compared to $5pp and $1pp for the impact of APM on OA progression and pain management costs, respectively.
given a WTP of $50,000/QALY. With time costs included, EVPPI for time costs was estimated at $59pp.

**Discussion**

We examined the cost-effectiveness of three strategies to treat symptomatic MT and OA: PT, PT followed by APM for patients who do not respond to PT, and immediate APM for all patients as a first-line treatment. Despite the fact that several RCTs failed to document the superiority of APM over non-operative treatment or placebo, our results suggest considerable uncertainty surrounding the question of which treatment is actually preferred from a cost-effectiveness standpoint. We found that PT alone was unlikely to be a preferred cost-effective strategy and that the current state of evidence is not sufficient to reject APM on cost-effectiveness grounds in all persons with MT and OA.

Sensitivity analyses demonstrated that as the effectiveness of Delayed APM improved, Immediate APM was associated with greater comparative costs and less comparative effectiveness. Upon quantifying the value of perfect information, we found that the maximum amount

---

**Fig 3. Cost-Effectiveness Acceptability Curve.** Fig 3 shows the proportion of iterations where a given strategy proved to be the most cost-effective (i.e., the strategy with the highest NMB whose ICER was below the WTP threshold), represented by the y-axis, given a specific WTP, represented by the x-axis. Time costs were not included.

doi:10.1371/journal.pone.0130256.g003
society would be willing to pay for better information was $752.3 million. This amount greatly exceeds the cost of conducting another randomized controlled trial; indeed, the cost of conducting the MeTeOR trial was less than $4 million.

Inclusion of time costs generally improved the value of both Delayed APM and Immediate APM since these strategies reduced the time subjects spent in pain, minimizing productivity losses over time. In fact, treatment-related costs represented only a small proportion of the total costs subjects accumulated, as time costs more than tripled the total costs incurred over ten years.

To the best of our knowledge, this is the first study to examine the economic implications of treatment strategies for symptomatic MT in the setting of knee OA and the first to quantify uncertainty in treatment decisions. Other studies that have evaluated the cost-effectiveness of knee arthroscopy [42] and anterior cruciate ligament (ACL) reconstruction [42–46] have reported ICERs well below $50,000/QALY for both procedures. While one analysis [45] used

---

**Fig 4. Cost-effectiveness Acceptability Frontier and Expected Value of Perfect Information.** Fig 4 contains two categories of reported results. The first is the cost-effectiveness acceptability frontier, described by solid gray and black lines at the top half of the graph. The frontier describes the likelihood that the strategy with highest NMB at any given WTP threshold is cost-effective, where likelihood is defined as a probability on the left-most Y axis. NMB is calculated by subtracting the cost of a treatment strategy from the product of a strategy’s effectiveness and a given WTP. The bottom half of the graph describes the EVPI reported for each WTP threshold for the strategy defined as preferred under that threshold. EVPI results are represented by dotted lines in dollars per person by the right-side Y axis. Time costs were not included.

doi:10.1371/journal.pone.0130256.g004
Monte Carlo simulation modeling to evaluate the effect of parameter uncertainty on results, the remainder based their findings on deterministic analyses.

The results of this analysis should be interpreted in view of certain limitations. Importantly, our analysis was conducted in mid-to-late 50 year olds with both MT and OA. Accordingly, these results should be generalized cautiously and may not be applicable for subjects reporting MT without OA, for subjects presenting with MT in their 30s or 40s (particularly those who might not be eligible for TKA), or for subjects reporting MT with end-stage (KL 4) OA, which was an exclusion criteria in the MeTeOR trial and hence not modeled in our analysis (patients with end-stage knee OA have poor prognosis for knee arthroscopy). We did not conduct the analysis separately for men and women. Since data from the MeTeOR trial did not reveal significant differences in outcome by gender or age, we chose not to conduct separate subgroup analyses. Should such outcome differences be observed elsewhere, it may prove useful to assess the cost-effectiveness of gender- and age-specific treatment strategies.

Moreover, while key efficacy parameters were derived from one large RCT, additional parameters related to OA pain over the 10 year time span were derived from larger long-term population-based studies. The large uncertainty underlying some key parameter estimates, such whether APM is as efficacious after a failed course of PT as it is soon upon diagnosis or whether APM affects the progression of OA, lends uncertainty to the estimated cost-effectiveness of the Delayed APM strategy. Our multiple sensitivity analyses examine the potential influence varying these important parameters may have on the robustness of our cost-effectiveness results. While we consistently find that Immediate APM is the most expensive strategy, it was only dominated in a sensitivity analysis where the efficacies of Delayed and Immediate APM were set as equal. Lastly, the wage rate is a defensible proxy for the opportunity cost of time only if we assume that the patient population is composed entirely of employed persons. In MeTeOR, about 60% of study participants were employed, with rates similar across both arms. Therefore, we likely underestimated the opportunity costs due to work-related absenteeism.

This work has critical implications for research, clinical care, and policy. While several large RCTs showed no superiority of APM compared to non-surgical or sham procedures, the impact of these trials on clinical practice may be limited. For example, the lack of superiority of APM compared to sham surgery does not illuminate a preferred treatment since sham is not used clinically. While substantial cross-over rates reported by other trials suggest that PT followed by APM if necessary (Delayed APM) may be a key clinical strategy, we know of no head-to-head studies comparing the effectiveness of that strategy and Immediate APM. While only a portion of patients will undergo surgery in the Delayed APM strategy, we kept it as a separate strategy because if APM were to be eliminated as a treatment option for persons with knee OA and MT, the Delayed APM strategy would be eliminated as well. These limitations in the application of trial results to clinical practice emphasize the crucial role of model-based evaluations in aiding medical decision-making.

Our results complement the results of recent RCTs by defining societal WTP thresholds at which surgical strategies may become preferred treatments. Moreover, we have quantified the amount of uncertainty surrounding these choices and offered a framework for prioritization of future research. Model-based evaluations of treatments for persons with MT and OA may help to frame policy recommendations and define research priorities regarding the optimal use of APM-based strategies.

Supporting Information

S1 Technical Appendix. The Technical Appendix provides additional details on the methodology, parameter derivation and reports additional results from sensitivity analyses. (DOCX)
Author Contributions

Conceived and designed the experiments: EL ADP JNK. Performed the experiments: EL EED ADP JNK. Analyzed the data: EL EED ADP YD JNK. Contributed reagents/materials/analysis tools: RJW KPS LAM MHJ RGM CESN. Wrote the paper: EL EED. Statistical expertise: EL YD. Critical revision of the article for important intellectual content: EL EED ADP YD RJW KPS LAM MHJ RGM CESN JNK. Final approval of the article: EL EED ADP YD RJW KPS LAM MHJ RGM CESN JNK. Obtained funding: EL JNK.

References

1. Englund M, Guermazi A, Gale D, Hunter DJ, Aliabadi P, Clancy M, et al. (2008) Incidental meniscal findings on knee MRI in middle-aged and elderly persons. N Engl J Med 359: 1108–1115. doi: 10.1056/NEJMoa0800777 PMID: 18784100

2. Cullen KA, Hall MJ, Golosinskiy A (2009) Ambulatory surgery in the United States, 2006. Natl Health Stat Report: 1–25.

3. Gauffin H, Tagesson S, Meunier A, Magnusson H, Kvist J (2014) Knee arthroscopic surgery is beneficial to middle-aged patients with meniscal symptoms: a prospective, randomised, single-blinded study. Osteoarthritis Cartilage 22: 1808–1816. doi: 10.1016/j.joca.2014.07.017 PMID: 25086401

4. Herrlin S, Hallander M, Wange P, Weidenhielm L, Werner S (2007) Arthroscopic or conservative treatment of degenerative medial meniscal tears: a prospective randomised trial. Knee Surg Sports Traumatol Arthrosc 15: 393–401. PMID: 17216272

5. Herrlin SV, Wange PO, Lapidus G, Hallander M, Werner S, Weidenhielm L (2013) Is arthroscopic surgery beneficial in treating non-traumatic, degenerative medial meniscal tears? A five year follow-up. Knee Surg Sports Traumatol Arthrosc 21: 358–364. doi: 10.1007/s00167-012-1960-3 PMID: 22437659

6. Katz JN, Brophy RH, Chaisson CE, de Chaves L, Cole BJ, Dahm DL, et al. (2013) Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med 368: 1675–1684. doi: 10.1056/NEJMoa1301408 PMID: 23506518

7. Sihvo nen R, Paavola M, Malmivaara A, Itala A, Joukainen A, Nummi H, et al. (2013) Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med 369: 2515–2524. doi: 10.1056/NEJMoa1305189 PMID: 24369076

8. Yim JH, Seon JK, Song EK, Choi JI, Kim MC, Lee KB, et al. (2013) Comparative study of meniscectomy and nonoperative treatment for degenerative horizontal tears of the medial meniscus. Am J Sports Med 41: 1565–1570. doi: 10.1177/0363546513488518 PMID: 23703915

9. Khan M, Evaniew N, Bedi A, Ayeni OR, Bhandari M (2014) Arthroscopic surgery for degenerative tears of the meniscus: a systematic review and meta-analysis. CMAJ 186: 1057–1064. doi: 10.1503/cmaj.140433 PMID: 25157057

10. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322–338. PMID: 8246705

11. Brandt KD, Fife RS, Braunstein EM, Katz B (1991) Radiographic grading of the severity of knee osteoarthritis: relation of the Kellgren and Lawrence grade to a grade based on joint space narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. Arthritis Rheum 34: 1381–1386. PMID: 1953815

12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253–1258. PMID: 8849754

13. Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40: 593–603. PMID: 3298297

14. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22: 290–308. PMID: 12150595

15. Briggs AH, Claxton K, Sculpher MJ (2006) Decision modelling for health economic evaluation. Oxford: Oxford University Press.

16. Weinstein AM, Rome BN, Reichmann WM, Collins JE, Burbine SA, Thomhill TS, et al. (2013) Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am 95: 385–392. doi: 10.2106/JBJS.L.00206 PMID: 23944005

17. (2014) Revised United States Life Tables, 2009. National Vital Statistics Reports: Centers for Disease Control and Prevention, US Department of Health and Human Services. PMID: 25493705
18. Jordan JM, Helmig CG, Renner JB, Luta G, Dragomir AD, Woodard J, et al. (2007) Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol 34: 172–180. PMID:17216685

19. Holt HL, Katz JN, Reichmann WM, Gerlovin H, Wright EA, Hunter DJ, et al. (2011) Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60–64 year-old US adults. Osteoarthritis Cartilage 19: 44–50. doi: 10.1016/j.joca.2010.10.009 PMID: 20955807

20. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. (2013) Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res (Hoboken) 65: 703–711. doi: 10.1002/acr.21898 PMID: 23203864

21. Katz JN, Mahomed NN, Baron JA, Barrett JA, Fossel AH, Creel AH, et al. (2007) Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum 56: 568–574. PMID:17265491

22. Hame SL, Nguyen V, Ellerman J, Ngo SS, Wang JC, Gamradt SC (2012) Complications of arthroscopic meniscectomy in the older population. Am J Sports Med 40: 1402–1405. doi:10.1177/0363546512443043 PMID: 22495145

23. Katz JN, Barrett J, Mahomed NN, Baron JA, Wright RJ, Losina E (2004) Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am 86-A: 1909–1916. PMID: 15342752

24. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95: 1681–1690. PMID: 10925968

25. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123: 241–249. PMID: 7611589

26. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080. PMID:15713944

27. (2012) Medicare Fee Schedules. Center for Medicare and Medicaid Services.

28. (2012) Medicare Hospital Outpatient Prospective Payment System, Addendum B. Centers for Medicare & Medicaid Services.

29. (2011) Medicare Hospital Inpatient Prospective Payment System. Centers for Medicare & Medicaid Services.

30. (2014) Red Book Online. Truven Health Analytics Inc.

31. (2011) Healthcare Cost and Utilization Project. Nationwide Inpatient Sample. Rockville, MD: Agency for Healthcare Research and Quality.

32. Buntin MB, Deb P, Escarce J, Hoverman C, Paddock S, Sood N (2005) Comparison of medicare spending and outcomes for beneficiaries with lower extremity: a study conducted by RAND Health for the Medicare Payment Advisory Commission. Arlington, VA: RAND Health.

33. (2013) May 2013 National Occupational Employment and Wage Estimates, United States. Washington, D.C.: US Bureau of Labor Statistics, Division of Occupational Employment Statistics.

34. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD (1998) Knee Injury and Osteoarthritis Outcome Score (KOOS)—development of a self-administered outcome measure. J Orthop Sports Phys Ther 28: 88–96. PMID: 9699158

35. Roos EM, Lohmander LS (2003) The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 1: 64. PMID: 14613558

36. Wolfe F, Hawley DJ (1997) Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 36: 786–793. PMID: 9255115

37. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H (1994) Validity of Euroqol—a generic health status instrument—in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 33: 655–662. PMID: 8019795

38. (1990) EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208. PMID: 10109801

39. Nahin R, Barnes P, Stussman B, Bloom B (2009) Costs of Complementary and Alternative Medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Hyattsville, MD: National Center for Health Statistics.

40. Toossi M (2012) Labor force projections to 2020: a more slowly growing workforce. US Bureau of Labor Statistics. 43–64 p.
41. Katz JN, Chaisson CE, Cole B, Guermazi A, Hunter DJ, Jones M, et al. (2012) The MeTeOR trial (Meniscal Tear in Osteoarthritis Research): rationale and design features. Contemp Clin Trials 33: 1189–1196. doi: 10.1016/j.cct.2012.08.010 PMID: 22968127

42. Lubowitz JH, Appleby D (2011) Cost-effectiveness analysis of the most common orthopaedic surgery procedures: knee arthroscopy and knee anterior cruciate ligament reconstruction. Arthroscopy 27: 1317–1322. doi: 10.1016/j.arthro.2011.06.001 PMID: 21855268

43. Gottlob CA, Baker CL Jr. (2000) Anterior cruciate ligament reconstruction: socioeconomic issues and cost effectiveness. Am J Orthop (Belle Mead NJ) 29: 472–476. PMID: 10890463

44. Gottlob CA, Baker CL Jr., Pellissier JM, Colvin L (1999) Cost effectiveness of anterior cruciate ligament reconstruction in young adults. Clin Orthop Relat Res: 272–282. PMID: 10546625

45. Farshad M, Gerber C, Meyer DC, Schwab A, Blank PR, Szucs T (2011) Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis. BMC Health Serv Res 11: 317. doi: 10.1186/1472-6963-11-317 PMID: 22098703

46. Mather RC 3rd, Hettrich CM, Dunn WR, Cole BJ, Bach BR Jr., Huston LJ, et al. (2014) Cost-effectiveness analysis of early reconstruction versus rehabilitation and delayed reconstruction for anterior cruciate ligament tears. Am J Sports Med 42: 1583–1591. PMID: 24801663